Clinical Trial Detail

NCT ID NCT01312376
Title Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
Recruitment Terminated
Gender female
Phase Phase I
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

peritoneal carcinoma

ovarian cancer

fallopian tube cancer

Therapies

Fludarabine

Cyclophosphamide

Bevacizumab

CD3/CD28 stimulated/primed autologous Ts

OC-DC vaccine

Age Groups: senior adult

No variant requirements are available.